2 results
Approved WMOPending
Primary ObjectiveThe primary efficacy objective of the study is to assess the effect of garetosmab (10 mg/kg) versus placebo on the formation of new HO lesions from baseline to week 56, as determined by low dose CT.The primary safety objective of…
Approved WMOCompleted
The main objectives of the trial are to demonstrate the effectiveness of BI 685509 and to characterize the dose-response relationship for BI 685509 in patients with DKD by assessing 3 doses and placebo.